For 24 years, Erchonia® has been committed to the research of low-level laser therapy (LLLT) through extensive clinical studies and has attained more than (18) FDA Market Clearances. Erchonia® made history in 2010 when the FDA gave Erchonia® market clearance for the first non-invasive fat loss laser in history. This created a new category for the FDA called OLI-Fat Reduction Laser, making Erchonia® the gold standard for low-level laser technology.
Erchonia’s green laser was proven and FDA Market Cleared in 3 separate double-blind clinical trials with no known side-effects and produces 23% more energy than our red lasers, making Emerald™ the safest and most effective way to treat fat.
Learn more about the double-blind, randomized, placebo-controlled trial of a 2-week noninvasive laser treatment conducted from May 2007 to June 2008 across multiple-private practice sites in the United States of America.
Erchonia’s low-level lasers create stimulation of cytochrome C oxidase, resulting in increased mitochondrial activity, resulting in increased ATP, NADH, and RNA and cellular respiration; increased nitric oxide synthase activity and nitric oxide production; and increased reactive oxygen species, which play an important role in cell signaling, cell cycle progression, enzyme activation, and synthesis of proteins and nucleic acids.
It should be noted that the release of lipids following LLLT does not elevate plasma lipids, plasma triglycerides or cholesterol.